List of Bludigo drug patents
Bludigo is owned by Provepharm Sas.
Bludigo contains Indigotindisulfonate Sodium.
Bludigo has a total of 2 drug patents out of which 0 drug patents have expired.
Bludigo was authorised for market use on 08 July, 2022.
Bludigo is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Bludigo from 2026-07-08.
The generics of Bludigo are possible to be released after 23 December, 2037.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10927258 | PROVEPHARM SAS | Process for the preparation of Indigotindisulfonate sodium (indigo carmine) |
Dec, 2037
(14 years from now) | |
| US11499050 | PROVEPHARM SAS | NA |
Dec, 2037
(14 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 8, 2027 |
Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient
NCE-1 date: 2026-07-08
Market Authorisation Date: 08 July, 2022
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
BLUDIGO family patents
3
United States
2
India
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic